Recombinant vaccine against COVID-19 based on a paramyxovirus viral vector
AssigneesLaboratorio Avi-Mex, S.A. De C.V., Icahn School of Medicine at Mount Sinai
InventorsBernardo Lozano-Dubernard, Ernesto Soto-Priante, David Sarfati-Mizrahi, Felipa Castro-Peralta, Georgina Paz-De La Rosa, Peter Palese, Adolfo Garcia-Sastre, Florian Krammer, Weina Sun
Life of this patent
Estimating the term…
Abstract
An active or inactivated recombinant vaccine against COVID-19 is described that comprises a Newcastle disease viral vector and a pharmaceutically acceptable carrier, adjuvant and/or excipient, characterized in that the viral vector is a virus capable of generating a cellular immune response that has a SARS-COV-2 exogenous nucleotide sequence inserted.
Claims36
A recombinant Newcastle disease virus (NDV) comprising a NDV viral vector comprising SEQ ID NO:6 or SEQ ID NO:14 and an exogenous nucleotide sequence encoding for antigenic sites of severe acute respiratory syndrome coronavirus 2 (SARS-COV-2), wherein the exogenous nucleotide sequence comprises an ectodomain of a spike (S) protein of SARS-COV-2 fused to a transmembrane domain and a cytoplasmic domain of a NDV fusion (F) protein, wherein the polybasic cleavage site of the ectodomain of the S protein is mutated to an alanine and amino acids that correspond to amino acids 817, 892, 899, 942, 986 and 987 of the ectodomain of the S protein of SEQ ID NO:11 are mutated to prolines, whereby the NDV viral vector and the antigenic sites are stable after at least 3 consecutive passages in chicken embryo.
A coronavirus disease 2019 (COVID-19) vaccine comprising:
- a recombinant Newcastle disease virus (NDV) comprising an NDV viral vector comprising SEQ ID NO:6 or SEQ ID NO:14 and an exogenous nucleotide sequence encoding for antigenic sites of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), wherein the exogenous nucleotide sequence comprises an ectodomain of a spike (S) protein of SARS-COV-2 fused to a transmembrane domain and a cytoplasmic domain of a NDV fusion (F) protein, wherein the polybasic cleavage site of the ectodomain of the S protein is mutated to an alanine and amino acids that correspond to amino acids 817, 892, 899, 942, 986 and 987 of the ectodomain of the S protein of SEQ ID NO:11 are mutated to prolines, whereby the NDV viral vector and the antigenic sites are stable after at least 3 consecutive passages in chicken embryo, and
- a pharmaceutically acceptable carrier, adjuvant and/or excipient.
Dependencies are inferred from the claim text.